The manufacturer is requesting that Genotropin be listed for use in adult patients with GHD. Somatropin, available through other brand names and products, is indicated for additional conditions such as idiopathic short stature and short stature homeobox-containing gene deficiency, for children born small for gestational age and for children with growth failure due to chronic renal failure. The potential for off-label use of Genotropin can be associated with considerable costs to the drug plans. However, it should be noted that this possibility of off-label use is not unique to Genotropin and applies to the other somatropin products on the market in Canada.
A CDR analysis of potential utilization in adult GHD patients in Canada (APPENDIX 1: UTILIZATION ANALYSIS) suggested that Genotropin could be associated with cost savings of up to $1,317,168 per year for public plans.
Publication Details
Copyright
You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.
Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher
Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)
NLM Citation
Somatropin (Genotropin) (0.15 mg/day to 0.3 mg/day): Replacement of Endogenous Growth Hormone in Adults with Growth Hormone Deficiency [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan. 4, ISSUES FOR CONSIDERATION.